This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Tacalcitol monohydrate topical

Updated 2 Feb 2023 | Vitamin D and analogues


Topical preparations containing tacalcitol

Drugs List

  • CURATODERM 4microgram/1g lotion
  • CURATODERM 4microgram/g ointment
  • tacalcitol 4microgram/1g lotion
  • tacalcitol 4microgram/g ointment
  • Therapeutic Indications


    Plaque psoriasis
    Psoriasis - scalp


    For the treatment for psoriasis vulgaris.


    For the treatment of psoriasis vulgaris, especially on the scalp.



    Apply sparingly once daily, preferably at bedtime to the affected areas. A maximum of 10 g of ointment, or 10 ml of lotion, can be applied each day. When ointment and lotion are used together, a maximum weekly dose of 280 micrograms of tacalcitol should not be exceeded (e.g. 30 ml of tacalcitol lotion and 40 g of tacalcitol ointment). The duration of treatment depends on the severity of the lesions, and should be decided by the physician.

    When tacalcitol is used in combination with UV radiation it increases the efficacy of treatment and shortens the radiation period. UV radiation should be given in the morning and tacalcitol ointment or lotion at bedtime.

    There is clinical trial experience with continuous and intermittent treatment in adults with tacalcitol ointment for up to eighteen months and with tacalcitol lotion for up to 8 weeks, which shows no serious or unexpected adverse reactions.

    Tacalcitol can be used on all areas of the body (including the face, hairline, scalp, axilla and other flexures). When used on the scalp the ointment can be shampooed out the next morning.


    (See Dosage; Adult)


    Children aged 12 to 18 years

    (See Dosage; Adult)

    Patients with Renal Impairment

    Monitor serum calcium levels in patients with renal impairment.


    Children under 12 years
    Disorder of calcium metabolism
    Psoriasis punctata
    Pustular psoriasis
    Severe cardiac disorder
    Severe hepatic impairment
    Severe renal impairment

    Precautions and Warnings

    Erythrodermic exfoliative psoriasis

    UV radiation treatment should be administered the morning before treatment
    Some formulations contain butylated hydroxy toluene (E321)
    Some formulations contain propylene glycol
    Advise patient to wash hands after use
    Avoid contact with eyes
    Breastfeeding: Do not treat the breast area if patient breastfeeding
    If accidental contact with the eyes occurs, rinse thoroughly with water
    Monitor serum calcium levels in patients with renal impairment
    Monitor serum calcium on prolonged use or with high doses of vitamin D
    Patient at risk of hypercalcaemia-monitor albumin corrected serum Ca levels
    Discontinue if hypercalcaemia occurs
    Avoid use on normal skin

    Pregnancy and Lactation


    Tacalcitol monohydrate is contraindicated during pregnancy.

    The manufacturer recommends that tacalcitol monohydrate should be avoided during pregnancy. No clinical data on exposed pregnancies are available. Animal studies have not demonstrated direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. The potential risk to humans is unknown.


    Tacalcitol monohydrate is contraindicated during breastfeeding.

    The manufacturer advises that tacalcitol monohydrate is not indicated for treatment during breastfeeding. Tacalcitol and its main metabolite pass into the milk of rats. It is not known whether tacalcitol is excreted in human milk. Risks to exposed infants is unknown.


    Patients should be advised to avoid contact with eyes. If accidental contact with the eyes occurs, the area should be thoroughly rinsed with water.

    Patients should be advised to wash their hands after use in order to prevent inadvertent transfer of the ointment/lotion to normal skin.

    Warn patient that the ointment contains white petrolatum and liquid paraffin, and application in the genital or anal area can reduce the functionality of latex products (e.g. condoms, diaphragms) when used simultaneously and thus impair the reliability of these products.

    Side Effects

    Burning sensation (local)
    Contact dermatitis
    Exacerbation of psoriasis
    Eye irritation
    Itching sensation (local)
    Mucosal irritation
    Skin reactions


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: August 2014

    Reference Sources

    Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press Accessed on August 11, 2014.

    Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications Accessed on August 11, 2014.

    Summary of Product Characteristics: Curatoderm ointment 4 micrograms/g. Reckitt Benckiser Healthcare. Revised February 2018.

    Summary of Product Characteristics: Curatoderm lotion 4 micrograms/g. Reckitt Benckiser Healthcare. Revised November 2021.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.